IRIS Accounts Production v24.2.0.383 14797374 Board of Directors 12.4.23 31.7.24 31.7.24 false true false false true false Ordinary shares 1.00000 Ordinary A shares 1.00000 1.00000 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh147973742023-04-11147973742024-07-31147973742023-04-122024-07-31147973742023-04-1114797374ns15:EnglandWales2023-04-122024-07-3114797374ns14:PoundSterling2023-04-122024-07-3114797374ns10:Director12023-04-122024-07-3114797374ns10:PrivateLimitedCompanyLtd2023-04-122024-07-3114797374ns10:SmallEntities2023-04-122024-07-3114797374ns10:AuditExempt-NoAccountantsReport2023-04-122024-07-3114797374ns10:SmallCompaniesRegimeForDirectorsReport2023-04-122024-07-3114797374ns10:SmallCompaniesRegimeForAccounts2023-04-122024-07-3114797374ns10:FullAccounts2023-04-122024-07-3114797374ns10:OrdinaryShareClass12023-04-122024-07-3114797374ns10:OrdinaryShareClass22023-04-122024-07-31147973741ns10:OrdinaryShareClass12023-04-122024-07-31147973742ns10:OrdinaryShareClass22023-04-122024-07-3114797374ns10:Director22023-04-122024-07-3114797374ns10:RegisteredOffice2023-04-122024-07-3114797374ns5:CurrentFinancialInstruments2024-07-3114797374ns5:ShareCapital2024-07-3114797374ns5:RetainedEarningsAccumulatedLosses2024-07-3114797374ns5:ComputerEquipment2023-04-122024-07-3114797374ns5:PlantMachinery2023-04-122024-07-3114797374ns5:PlantMachinery2024-07-3114797374ns5:WithinOneYearns5:CurrentFinancialInstruments2024-07-3114797374ns5:CurrentFinancialInstruments2023-04-122024-07-3114797374ns5:DeferredTaxation2023-04-122024-07-3114797374ns5:DeferredTaxation2024-07-3114797374ns10:OrdinaryShareClass12024-07-3114797374ns10:OrdinaryShareClass22024-07-31
REGISTERED NUMBER: 14797374 (England and Wales)











Unaudited Financial Statements

for the Period 12 April 2023 to 31 July 2024

for

Cogent Biosciences Ltd
Trading as
Convincente

Cogent Biosciences Ltd (Registered number: 14797374)
Trading as Convincente






Contents of the Financial Statements
for the Period 12 April 2023 to 31 July 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Cogent Biosciences Ltd
Trading as Convincente

Company Information
for the Period 12 April 2023 to 31 July 2024







DIRECTORS: Mrs A J Harrop
Dr J A Harrop





REGISTERED OFFICE: Eldo House
Kempson Way
Bury St Edmunds
Suffolk
IP32 7AR





REGISTERED NUMBER: 14797374 (England and Wales)





ACCOUNTANTS: Knights Lowe Chartered Accountants
Eldo House
Kempson Way
Suffolk Business Park
Bury St Edmunds
Suffolk
IP32 7AR

Cogent Biosciences Ltd (Registered number: 14797374)
Trading as Convincente

Balance Sheet
31 July 2024

Notes £    £   
FIXED ASSETS
Tangible assets 4 993

CURRENT ASSETS
Debtors 5 4,920
Cash at bank 17,338
22,258
CREDITORS
Amounts falling due within one year 6 20,771
NET CURRENT ASSETS 1,487
TOTAL ASSETS LESS CURRENT LIABILITIES 2,480

PROVISIONS FOR LIABILITIES 7 189
NET ASSETS 2,291

CAPITAL AND RESERVES
Called up share capital 8 200
Retained earnings 2,091
SHAREHOLDERS' FUNDS 2,291

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 July 2024.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 July 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Cogent Biosciences Ltd (Registered number: 14797374)
Trading as Convincente

Balance Sheet - continued
31 July 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 4 October 2024 and were signed on its behalf by:





Dr J A Harrop - Director


Cogent Biosciences Ltd (Registered number: 14797374)
Trading as Convincente

Notes to the Financial Statements
for the Period 12 April 2023 to 31 July 2024

1. STATUTORY INFORMATION

Cogent Biosciences Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. Income is recognised in the accounts when the company receives the right to receive consideration for services provided.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Computer equipment - 33% on cost

Financial instruments
The company only enters into basic financial instrument transactions that result in recognition of financial assets and liabilities. Basic financial instruments are recognised at amortised cost.

Taxation
Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Cogent Biosciences Ltd (Registered number: 14797374)
Trading as Convincente

Notes to the Financial Statements - continued
for the Period 12 April 2023 to 31 July 2024

2. ACCOUNTING POLICIES - continued

Impairment
At each reporting date, goodwill and other fixed assets, including tangible fixed assets and investments but excluding investment properties, are assessed to determine whether there is an indication that the carrying amount of an asset may be more than its recoverable amount and that the asset should be impaired. If there is an indication of possible impairment, the recoverable amount of an asset, which is the higher of its value in use and its net realisable value, is estimated and compared with its carrying amount. If the recoverable amount is lower, the carrying amount of the asset is written down to its estimated recoverable amount and an impairment loss is recognised in profit and loss.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was 2 .

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
Additions 1,334
At 31 July 2024 1,334
DEPRECIATION
Charge for period 341
At 31 July 2024 341
NET BOOK VALUE
At 31 July 2024 993

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
£   
Trade debtors 4,920

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
£   
Taxation and social security 6,024
Other creditors 14,747
20,771

Other creditors includes a directors loan.

7. PROVISIONS FOR LIABILITIES
£   
Deferred tax
Accelerated capital allowances 189

Cogent Biosciences Ltd (Registered number: 14797374)
Trading as Convincente

Notes to the Financial Statements - continued
for the Period 12 April 2023 to 31 July 2024

7. PROVISIONS FOR LIABILITIES - continued

Deferred
tax
£   
Charge to Income Statement during period 189
Balance at 31 July 2024 189

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal
value: £   
150 Ordinary shares £1 150
50 Ordinary A shares £1 50
200

The following shares were allotted and fully paid for cash at par during the period:

150 Ordinary shares shares of £1 each
50 Ordinary A shares shares of £1 each